{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:24:15Z","timestamp":1793042655467,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100012097","name":"Association Vaincre le M\u00e9lanome","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association pour la Recherche et l\u2019Enseignement en Pathologie (AREP)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Dermatol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12895-017-0061-x","type":"journal-article","created":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T13:08:25Z","timestamp":1498914505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Variation of mutant allele frequency in NRAS Q61 mutated melanomas"],"prefix":"10.1186","volume":"17","author":[{"given":"Zofia","family":"H\u00e9lias-Rodzewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Terrones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Beauchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristi","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"key":"61_CR1","first-page":"1363","volume":"4","author":"AP Albino","year":"1989","unstructured":"Albino AP, Nanus DM, Mentle IR, Cordon-Cardo C, McNutt NS, Bressler J, et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene. 1989;4:1363\u201374.","journal-title":"Oncogene"},{"key":"61_CR2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949\u201354.","journal-title":"Nature"},{"key":"61_CR3","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135\u201347.","journal-title":"N Engl J Med"},{"key":"61_CR4","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1101\/gad.191999.112","volume":"26","author":"H Tsao","year":"2012","unstructured":"Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012;26:1131\u201355.","journal-title":"Genes Dev"},{"key":"61_CR5","unstructured":"Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. 2015. Cell 2015, 161:1681\u20131696."},{"key":"61_CR6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239\u201346.","journal-title":"J Clin Oncol"},{"key":"61_CR7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","volume":"15","author":"WO Greaves","year":"2013","unstructured":"Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 2013;15:220\u20136.","journal-title":"J Mol Diagn"},{"key":"61_CR8","first-page":"6483","volume":"9","author":"K Omholt","year":"2003","unstructured":"Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9:6483\u20138.","journal-title":"Clin Cancer Res"},{"key":"61_CR9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.0022-202X.2005.23788.x","volume":"125","author":"LA Akslen","year":"2005","unstructured":"Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol. 2005;125:312\u20137.","journal-title":"J Invest Dermatol"},{"key":"61_CR10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1476-4598-13-45","volume":"13","author":"J Thumar","year":"2014","unstructured":"Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM. MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer. 2014;13:45.","journal-title":"Mol Cancer"},{"key":"61_CR11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","volume":"24","author":"B Devitt","year":"2011","unstructured":"Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 2011;24:666\u201372.","journal-title":"Pigment Cell Melanoma Res"},{"key":"61_CR12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","volume":"17","author":"JA Ellerhorst","year":"2011","unstructured":"Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011;17:229\u201335.","journal-title":"Clin Cancer Res"},{"key":"61_CR13","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","volume":"118","author":"JA Jakob","year":"2012","unstructured":"Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118:4014\u201323.","journal-title":"Cancer"},{"key":"61_CR14","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. BRIM-3 study group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507\u201316.","journal-title":"N Engl J Med"},{"key":"61_CR15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358\u201365.","journal-title":"Lancet"},{"key":"61_CR16","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877\u201388.","journal-title":"N Engl J Med"},{"key":"61_CR17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444\u201351.","journal-title":"Lancet"},{"key":"61_CR18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30\u20139.","journal-title":"N Engl J Med"},{"key":"61_CR19","doi-asserted-by":"crossref","unstructured":"Dummer R, Schadendorf D, Ascierto PA, Arance Fern\u00e1ndez AM, Dutriaux C, Maio M,et al. Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. J Clin Oncol 2016, ASCO Meeting Abstracts 34:9500.","DOI":"10.1200\/JCO.2016.34.15_suppl.9500"},{"key":"61_CR20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s12885-015-1515-3","volume":"15","author":"Z H\u00e9lias-Rodzewicz","year":"2015","unstructured":"H\u00e9lias-Rodzewicz Z, Funck-Brentano E, Baudoux L, Jung CK, Zimmermann U, Marin C, et al. Variations of BRAF mutant allele percentage in melanomas. BMC Cancer. 2015;15:497.","journal-title":"BMC Cancer"},{"key":"61_CR21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/CMR.0000000000000088","volume":"24","author":"C Lebb\u00e9","year":"2014","unstructured":"Lebb\u00e9 C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, et al. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma. Melanoma Res. 2014;24:415\u20138.","journal-title":"Melanoma Res"},{"key":"61_CR22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmoldx.2012.09.001","volume":"15","author":"E Colomba","year":"2013","unstructured":"Colomba E, H\u00e9lias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn. 2013;15:94\u2013100.","journal-title":"J Mol Diagn"},{"issue":"19","key":"61_CR23","first-page":"4314","volume":"2012","author":"S Moreau","year":"2012","unstructured":"Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, H\u00e9lias-Rodzewicz Z, et al. Prognostic value of BRAFV600 mutations inmelanoma patients after resection of metastatic lymph nodes. Ann SurgOncol. 2012;2012(19):4314\u201321.","journal-title":"Ann SurgOncol"},{"issue":"13","key":"61_CR24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmoldx.2011.03.002","volume":"2011","author":"K Balschun","year":"2011","unstructured":"Balschun K, Haag J, Wenke AK, von Sch\u00f6nfels W, Schwarz NT, R\u00f6cken C. KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. J Mol Diagn. 2011;2011(13):436\u201345.","journal-title":"J Mol Diagn"},{"key":"61_CR25","first-page":"246","volume":"13","author":"N Louren\u00e7o","year":"2014","unstructured":"Louren\u00e7o N, H\u00e9lias-Rodzewicz Z, Bachet JB, Brahimi-Adouane S, Jardin F. Tran van Nhieu J, Peschaud F, Martin E, Beauchet A, Chibon F. Emile JF Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors Mol Cancer. 2014;13:246.","journal-title":"Emile JF Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors Mol Cancer"},{"key":"61_CR26","doi-asserted-by":"crossref","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO,et al Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013, 6:pl1.","DOI":"10.1126\/scisignal.2004088"},{"key":"61_CR27","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jaad.2015.01.012","volume":"72","author":"M Ilie","year":"2015","unstructured":"Ilie M, Long-Mira E, Funck-Brentano E, Lassalle S, Butori C, Lespinet-Fabre V, et al. Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma. J Am Acad Dermatol. 2015 May;72:786\u201393.","journal-title":"J Am Acad Dermatol"},{"key":"61_CR28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/exd.13001","volume":"25","author":"E Funck-Brentano","year":"2016","unstructured":"Funck-Brentano E, H\u00e9lias-Rodzewicz Z, Longvert C, Mokhtari K, Saiag P, Emile JF. Increase in NRAS mutant allele percentage during metastatic melanoma progression. Exp Dermatol. 2016;25:472\u20134.","journal-title":"Exp Dermatol"},{"key":"61_CR29","volume":"4","author":"J Soh","year":"2009","unstructured":"Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One. 2009;4:e7464.","journal-title":"PLoS One"},{"key":"61_CR30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/2159-8290.CD-13-0096","volume":"3","author":"J Xu","year":"2013","unstructured":"Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, et al. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 2013;3:993\u20131001.","journal-title":"Cancer Discov"},{"key":"61_CR31","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.1073\/pnas.0900343106","volume":"106","author":"X Chen","year":"2009","unstructured":"Chen X, Mitsutake N, LaPerle K, Akeno N, Zanzonico P, Longo VA, et al. Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A. 2009;106:7979\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"61_CR32","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1038\/onc.2013.489","volume":"33","author":"X Chen","year":"2014","unstructured":"Chen X, Makarewicz JM, Knauf JA, Johnson LK, Fagin JA. Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition. Oncogene. 2014;33:5442\u20139.","journal-title":"Oncogene"},{"key":"61_CR33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/gcc.20785","volume":"49","author":"A Gast","year":"2010","unstructured":"Gast A, Scherer D, Chen B, Bloethner S, Melchert S, Sucker A, et al. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer. 2010;49:733\u201345.","journal-title":"Genes Chromosomes Cancer"},{"issue":"41","key":"61_CR34","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/cup.12389","volume":"2014","author":"E Dubruc","year":"2014","unstructured":"Dubruc E, Balme B, Dijoud F, Disant F, Thomas L, Wang Q, et al. Mutated and amplified NRAS in a subset of cutaneous melanocytic lesions with dermal spitzoid morphology: report of two pediatric cases located on the ear. J Cutan Pathol. 2014;2014(41):866\u201372.","journal-title":"J Cutan Pathol"},{"key":"61_CR35","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1158\/0008-5472.CAN-06-4152","volume":"67","author":"M Stark","year":"2007","unstructured":"Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2007;67:2632\u201342.","journal-title":"Cancer Res"},{"issue":"7","key":"61_CR36","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/1541-7786.MCR-08-0532","volume":"2009","author":"B Modrek","year":"2009","unstructured":"Modrek B, Ge L, Pandita A, Lin E, Mohan S, Yue P, et al. Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res. 2009;2009(7):1244\u201352.","journal-title":"Mol Cancer Res"},{"key":"61_CR37","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","volume":"121","author":"E Rumi","year":"2013","unstructured":"Rumi E, Pietra D, Guglielmelli P, Bordoni R, Casetti I, Milanesi C, et al. Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013;121:4388\u201395.","journal-title":"Blood"},{"issue":"68","key":"61_CR38","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","volume":"2008","author":"AJ Dunbar","year":"2008","unstructured":"Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;2008(68):10349\u201357.","journal-title":"Cancer Res"}],"container-title":["BMC Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12895-017-0061-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T01:32:48Z","timestamp":1589765568000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcdermatol.biomedcentral.com\/articles\/10.1186\/s12895-017-0061-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["61"],"URL":"https:\/\/doi.org\/10.1186\/s12895-017-0061-x","relation":{},"ISSN":["1471-5945"],"issn-type":[{"value":"1471-5945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,1]]},"article-number":"9"}}